小剂量糖皮质激素治疗HBV相关慢加急性肝衰竭的效果观察

邱波; 朱玲; 王堂明; 严世春; 张建明; 谢智安; 刘星妤

doi:10.3969/j.issn.1001-5256.2016.07.017

小剂量糖皮质激素治疗HBV相关慢加急性肝衰竭的效果观察

DOI: 10.3969/j.issn.1001-5256.2016.07.017

攀枝花市疾病预防控制中心攀枝花市第四人民医院肝病治疗中心

基金项目:

四川省攀枝花市科学与技术产权局科研项目(2016CY-S-16-3)；

详细信息

中图分类号: R512.62;R575.3
计量
- 文章访问数: 2172
- HTML全文浏览量: 43
- PDF下载量: 487
- 被引次数: 0
出版历程
- 出版日期: 2016-07-20

Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure

Research funding:

摘要

摘要: 目的探讨小剂量糖皮质激素治疗HBV相关慢加急性肝衰竭（HBV-ACLF）的疗效和安全性。方法收集2012年1月-2015年10月于攀枝花市第四人民医院肝病治疗中心诊治的HBV-ACLF患者118例。将纳入患者随机分为治疗组和对照组,每组各59例。所有患者均予以恩替卡韦抗病毒治疗和常规护肝、对症治疗,治疗组在此基础上加用小剂量氢化可的松琥珀酸钠（25 mg/d）静滴治疗。观察记录所有患者临床表现、肝功能生化指标、不良反应、住院时间及治疗费用情况等。计量资料组内比较采用配对t检验,组间比较采用t检验,计数资料组间比较采用χ2检验或Fisher精确概率法。结果疗程结束时,治疗组患者肝功能生化指标（ALT、AST、TBil、白蛋白、胆碱酯酶、凝血酶原活动度）改善情况均好于对照组,差异均有统计学意义（P值均<0.001）;治疗组患者住院天数[（48.0±9.2）d vs（74.0±16.4）d]及住院费用[（7974.5±853.7）元/人次vs（12 432.7±1263.1）元/人次]均低于对照组,差异均有统计学意义（t值分别为4.34、22.46,P值均<...
- 肝炎病毒,乙型 /
- 肝功能衰竭 /
- 糖皮质激素类 /
- 治疗
Abstract: Objective To investigate the efficacy and safety of low- dose glucocorticoids in the treatment of HBV- related acute- on-chronic liver failure( HBV- ACLF). Methods A total of 118 patients with HBV- ACLF who were treated in Center for Liver Disease Treatment in the Fourth People's Hospital of Panzhihua from January 2012 to October 2015 were enrolled and randomly divided into treatment group and control group,with 59 patients in each group. All the patients were given antiviral therapy with entecavir and conventional liver-protecting and symptomatic treatment,and the patients in the treatment group were given intravenous drip of low- dose hydrocortisone sodium succinate( 25 mg / d) in addition. The clinical manifestations,biochemical parameters for liver function,adverse events,length of hospital stay,and hospital costs were recorded for all patients. The t- test was used for comparison of continuous data between groups,the paired t- test was used for comparison of continuous data within groups,and the chi- square test or Fisher's exact test was used for comparison of categorical data between groups. Results At the end of the course of the treatment,the treatment group showed significantly better improvements in the biochemical parameters for liver function( alanine aminotransferase,aspartate aminotransferase,total bilirubin,albumin,cholinesterase,and prothrombin activity) compared with the control group( all P < 0. 001). The treatment group had a significantly shorter length of hospital stay and significantly lower hospital costs than the control group( length of hospital stay: 48. 0 ± 9. 2 d vs 74. 0 ± 16. 4 d,t = 4. 34,P < 0. 01; hospital costs: 7974. 5 ± 853. 7 RMB / person vs 12 432. 7 ± 1263. 1 RMB / person,t = 22. 46,P < 0. 01). No patients in the treatment group experienced adverse events related to hydrocortisone sodium succinate. Conclusion In the treatment of HBV- ACLF,low- dose hydrocortisone sodium succinate can eliminate jaundice,alleviate conditions,and improve the prognosis. Meanwhile,it can also shorten the length of hospital stay and reduce hospital costs. This drug has good safety and holds promise for further clinical research.
- hepatitis B virus /
- liver failure /
- glucocorticoids /
- therapy

HTML全文

参考文献(20)

[1]ZHANG YL,HAN T,ZHANG M,et al.Research progress in prognostic markers of acute-on-chronic liver failure[J].J Clin Hepatol,2014,30(10):1078-1081.(in Chinese)张玉玲,韩涛,张敏,等.慢加急性肝衰竭预后标志物的研究进展[J].临床肝胆病杂志,2014,30(10):1078-1081.

[2] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,CMA;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,CMA.Guideline for diagnosis and treatment of liver failure(2012 version)[J].Chin J Clin Infect Dis,2012,5(6):321-327.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝治疗组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327.

[3]LIU H,CHEN G,GAN XM.Research advances in new approaches to treatment of acute-on-chronic liver failure[J].J Clin Hepatol,2015,31(9):1496-1500.(in Chinese)刘洪,陈刚,甘雪梅.慢加急性肝衰竭治疗的新技术及其研究进展[J].临床肝胆病杂志,2015,31(9):1496-1500.

[4]ZHANG XQ,NIE QH.Application and effect of glucocorticoids in treatment of severe hepatitis[J].J Pract Hepatol,2004,7(2):70-72.(in Chinese)张绪清,聂青和.糖皮质激素在治疗重型肝炎中的应用及评价[J].实用肝脏病杂志,2004,7(2):70-72.

[5]LI LJ,REN H.Infectious Diseases[M].8th ed.Beijing:People's Medical Publishing House,2013:29-30.(in Chinese)李兰娟,任红.传染病学[M].8版.北京:人民卫生出版社,2013:29-30.

[6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[7]WANG TM,QIU B,LI SM,et al.Clinical efficacy of lamivudine and thymosinα1 combined with artificial extracorporeal liver support therapy in treatment of severe hepatitis B[J].Chin Hepatol,2008,13(2):145-147.(in Chinese)王堂明,邱波,李树民,等.拉米夫定、胸腺肽α1联合人工肝治疗重型乙型肝炎的临床研究[J].肝脏,2008,13(2):145-147.

[8]XIA SL,HE XF.Efficacy of entecavir treatment for patients with chronic hepatitis B[J].J Clin Hepatol,2015,31(4):523-525.(in Chinese)夏淑林,何小峰.恩替卡韦治疗慢性乙型肝炎的疗效观察[J].临床肝胆病杂志,2015,31(4):523-525.

[9]DENG ZP.Efficacy and safety of entecavir on hepatitis B[J].Chin J New Drugs Clin Remed,2005,24(4):326-329.(in Chinese)邓中平.恩替卡韦治疗乙型肝炎的疗效及安全性[J].中国新药与临床杂志,2005,24(4):326-329.

[10] COURSIN DB,WOOD KE.Corticosteroid supplementation for adrenal insufficiency[J].JAMA,2002,287(2):236-240.

[11]JIANG XH,GU XB.Change in serum cortisol concentration in patients with severe chronic hepatitis and its clinical significance[J].Jiangsu Med J,2004,30(6):464.(in Chinese)蒋祥虎,顾锡炳.慢性重型肝炎血清皮质醇浓度的变化及临床意义[J].江苏医药杂志,2004,30(6):464.

[12]ZHANG L,HAN F,WU D,et al.Relationship between sera hydrocortisone level and the prognosis of fulminant hepatitis[J].JClin Hepatol,2011,27(5):538-539.(in Chinese)张琳,韩峰,吴丹,等.血清皮质醇水平与重型肝炎预后的相关性[J].临床肝胆病杂志,2011,27(5):538-539.

[13]WANG HH.Low-dose corticosteroid therapy for tendency to subacute severe hepatitis:an analysis of 46 cases[J].Pract Clin Med,2001,2(4):22,24.(in Chinese)王汉华.小剂量激素治疗亚急性重症肝炎倾向46例[J].实用临床医学,2001,2(4):22,24.

[14]SUN S.Low-dose corticosteroid therapy for acute hepatitis E-associated hyperbilirubinemia:an analysis of 17 cases[J].Chin J Integr Tradit West Med Liver Dis,2002,12(5):299.(in Chinese)孙苏.小剂量激素治疗急性戊型肝炎高胆红素血症17例[J].中西医结合肝病杂志,2002,12(5):299.

[15]LEI NF,LIU TH,HE ZY.Analysis of blocking effect and safety of glucocorticoid de-escalation combined with antiviral therapy in the treatment of early severe hepatitis B[J].China Prac Med,2015,10(30):5-7.(in Chinese)雷南凤,刘添皇,何宗运.糖皮质激素降阶梯联合抗病毒治疗对早期乙型重症肝炎的阻断效果及安全性分析[J].中国实用医药,2015,10(30):5-7.

[16]CHEN CX,LIU B,GUO SM,et al.Glycocorticosteroid administration prevents occurrence of necrotic hepatitis in patients with chronic hepatitis B of severe degree[J].J Trop Dis Parasitol,2004,2(2):68-74,105.(in Chinese)陈从新,刘波,郭顺明,等.应用糖皮质激素治疗慢性乙型肝炎重度患者阻断坏死性肝炎的发生[J].热带病与寄生虫学,2004,2(2):68-74,105.

[17]ZHOU XS,WAN MB,XUE JY,et al.Effects of glucocorticoids combined with antiviral therapy in treatment of patients with chronic severe hepatitis B[J].J Clin Hepatol,2008,24(2):101-103.(in Chinese)周先珊,万谟彬,薛建亚,等.抗病毒基础上应用糖皮质激素治疗慢性重型乙型肝炎临床分析[J].临床肝胆病杂志,2008,24(2):101-103.

[18]WU JY,LI M,ZHANG H.Effect of glucocorticoid treatment on the clinical ontcome of patients with early-stage liver failure[J].JSouth Med Univ,2011,31(3):554-556.(in Chinese)吴锦瑜,黎明,张华.糖皮质激素治疗对早期肝衰竭患者转归的影响[J].南方医科大学学报,2011,31(3):554-556.

[19]YANG XK,XU GS.Efficacy of glucocorticoid in treatment of HBV-related hepatic failure:a meta-analysis[J].Med J Chin PLA,2013,38(7):581-584.(in Chinese)杨晓鲲,徐贵森.糖皮质激素治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].解放军医学杂志,2013,38(7):581-584.

[20]SONG P,LIU W,LIU TJ,et al.Efficacy and safety of glucocorticoids in treatment of severe chronic hepatitis B:a meta-analysis[J].Chongqing Med,2015,44(24):3407-3410.(in Chinese)宋攀,刘伟,刘天杰,等.糖皮质激素对慢性重度乙型肝炎疗效及安全性的Meta分析[J].重庆医学,2015,44(24):3407-3410.

施引文献

资源附件(0)

访问统计